Symbol / Company MBP / METABOLIC PHARMACEUTICALS LIMITED Date Picked 30-11-2005 Price When Picked $0.470 Company Overview Metabolic Pharmaceuticals Limited has the mission of developing novel therapies for diseases with application to worldwide markets, including obesity, obesity-related diseases such as type 2 diabetes, and more recently, pain, and osteoporosis.
The company's operating strategy is to outsource much of its activities, minimising infrastructure and overhead costs while maximising access to world-class expertise. Contract research organisations and other contract developers are being used for all aspects of the company's pharmaceutical developments, including formulation, manufacturing, preclinical studies and clinical studies. These outsourcing activities are closely controlled by the company's management, which has the benefit of substantial skills and experience in the clinical development of drugs, the management of research and a high-level of decision-making experience in the international pharmaceutical industry.
Metabolic also has established modern laboratories at the Baker Heart Research Institute (Melbourne) for some in-house activities.
Future Earnings Per Share Y1 Y2 Y3 0.050 0.020 0.020 (Expected dollar earnings per number of shares on issue) Nielsen Indicator Buying Level There has been a significant increase in buyer demand over the last couple of weeks Weekly Trend Analysis Downtrend Daily Trend Analysis Downtrend Short Term Support $0.445 Short Term Resistance $0.55 Broker Analysis Num. Analysts in Sample Recommendation 1 Strong Buy
Director Activity Date Director Action Volume Average Price Total Consideration 30-08-2005 Roland Scollay BUY 20,000 $0.600 $12,000 24-11-2005 Patrick Sutch BUY 15,000 $0.440 $6,600 25-11-2005 Robyn Baker BUY 23,000 $0.440 $10,235
View Director Activity Chart Graph
Top Bar - Stock Price Bottom Bar - Nielsen Indicator
MBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
